Mirum PharmaceuticalsMIRM
Market Cap: $1.93B
About: Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Employees: 294
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
125% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 9 (+5) [Q2]
49% more call options, than puts
Call options by funds: $3.64M | Put options by funds: $2.44M
35% more capital invested
Capital invested by funds: $1.34B [Q1] → $1.81B (+$469M) [Q2]
28% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 50
2.28% less ownership
Funds ownership: 114.96% [Q1] → 112.69% (-2.28%) [Q2]
7% less funds holding
Funds holding: 170 [Q1] → 158 (-12) [Q2]
32% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 37
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
14 analyst ratings
Cantor Fitzgerald Josh Schimmer 63% 1-year accuracy 46 / 73 met price target | 48%upside $60 | Overweight Maintained | 8 Aug 2024 |
Evercore ISI Group Gavin Clark-Gartner 64% 1-year accuracy 7 / 11 met price target | 63%upside $66 | Outperform Maintained | 8 Aug 2024 |
Baird Brian Skorney 50% 1-year accuracy 7 / 14 met price target | 9%upside $44 | Outperform Maintained | 8 Aug 2024 |
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 141 met price target | 63%upside $66 | Buy Reiterated | 26 Jul 2024 |
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 141 met price target | 63%upside $66 | Buy Reiterated | 8 Jul 2024 |
Financial journalist opinion
Based on 4 articles about MIRM published over the past 30 days